Scientists test new prostate disease drug

March 27, 2008

A Canadian-headquartered biopharmaceutical company is conducting the second Phase 3 study of a new drug designed to treat prostate disease.

Aeterna Zentaris Inc. said the double-blind study to be conducted in Europe will test the clinical effectiveness of cetrorelix, a luteinizing hormone-releasing drug for the treatment of benign prostatic hyperplasia, or BPH -- a non-cancerous enlargement of the prostate that causes disturbances in urination.

In the second Phase 3 study, 400 male patients will enter a four-week, no-treatment observation period and then be randomly assigned to either receive cetrorelix or a placebo. Effectiveness will based on a test that measures the severity and stability of voiding prostate symptoms.

The company's first study of the effectiveness of cetrorelix began in April 2007 and is continuing in Canada, Europe and the United States.

Copyright 2008 by United Press International

Explore further: Multiple allergic reactions traced to single protein

Related Stories

Multiple allergic reactions traced to single protein

December 17, 2014

Johns Hopkins and University of Alberta researchers have identified a single protein as the root of painful and dangerous allergic reactions to a range of medications and other substances. If a new drug can be found that ...

Recommended for you

Universal flu vaccine designed by scientists

September 30, 2016

An international team of scientists have designed a new generation of universal flu vaccines to protect against future global pandemics that could kill millions.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.